Edition:
United Kingdom

Pharmaceuticals

Page 1

Vistin Pharma Appoints New CFO

Monday, 2 Dec 2019

Dec 2 (Reuters) - Vistin Pharma ASA ::REG-VISTIN PHARMA ASA: APPOINTMENT OF NEW CFO.ALEXANDER KARLSEN HAS BEEN APPOINTED NEW CFO OF VISTIN PHARMA.WILL TAKE UP POSITION FROM 1 MARCH, 2020.

National Medical Products Administration Approves Chipscreen Bioscience's Chidamide For Breast Cancer Indication

Friday, 29 Nov 2019

Nov 29 (Reuters) - Shenzhen Chipscreen Biosciences Co Ltd <688321.SS>::NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) APPROVES CHIPSCREEN BIOSCIENCE'S CHIDAMIDE (EPIDAZA) FOR BREAST CANCER INDICATION.

Grindeks As 9 Months 2019 Profit At EUR 8.9 Million, Up 17% YoY

Thursday, 28 Nov 2019

Nov 28 (Reuters) - Grindeks AS ::9 MONTHS 2019 TURNOVER EUR 106.6 MILLION, UP 4% YOY.9 MONTHS 2019 PROFIT AFTER MINORITY INTEREST EUR 8.9 MILLION, UP 17% YOY.

Alliance Pharma Announces Return Of Xonvea Licensing Rights

Wednesday, 27 Nov 2019

Nov 27 (Reuters) - Alliance Pharma PLC ::RETURN OF XONVEA LICENSING RIGHTS.REACHED AGREEMENT WITH DUCHESNAY INC. OF CANADA TO RETURN UK AND EU LICENSING RIGHTS TO XONVEA.XONVEA IS A PRESCRIPTION MEDICINE FOR TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY WHERE CONSERVATIVE MANAGEMENT HAS FAILED.UNDER TERMS OF AGREEMENT, £2.0M PAYMENTS MADE BY ALLIANCE WILL BE REPAID TO GROUP, £0.25M IN 2019 AND BALANCE IN 2020.EXPECTS TO REDEPLOY PLANNED INVESTMENT IN XONVEA IN 2020 AND BEYOND INTO ITS GROWTH BRANDS AND DEVELOPMENT OF INTERNATIONAL OPERATIONS.

Johnson & Johnson Reports 9.3% Passive Stake In BiomX As Of October 28

Tuesday, 26 Nov 2019

Nov 26 (Reuters) - Johnson & Johnson ::JOHNSON & JOHNSON REPORTS 9.3% PASSIVE STAKE IN BIOMX INC AS OF OCTOBER 28 - SEC FILING.

Botanix Pharma Says US DEA Advised Its Synthetic Cannabidiol No Longer Scheduled As Controlled Substance

Sunday, 24 Nov 2019

Nov 25 (Reuters) - Botanix Pharmaceuticals Ltd ::US DEA ADVISED PARTNER PURISYS THAT SYNTHETIC CANNABIDIOL PRODUCED BY THEM, USED BY CO NO LONGER SCHEDULED AS CONTROLLED SUBSTANCE.

Novartis To Acquire The Medicines Company For $9.7 bln

Sunday, 24 Nov 2019

Nov 24 (Reuters) - Novartis Ag ::REG-NOVARTIS TO ACQUIRE THE MEDICINES COMPANY FOR USD 9.7 BN, ADDING INCLISIRAN, A POTENTIALLY TRANSFORMATIONAL INVESTIGATIONAL CHOLESTEROL-LOWERING THERAPY TO ADDRESS LEADING GLOBAL CAUSE OF DEATH.OFFER PRICE OF USD 85.00 PER SHARE.NOVARTIS - DEAL EXPECTED TO MODESTLY DILUTE CORE EPS VERSUS A NO DEAL SCENARIO DURING NEXT FEW YEARS AS CO INVESTS FOR A SUCCESSFUL LAUNCH OF INCLISIRAN.TRANSACTION HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES.NOVARTIS PLANS TO FINANCE TRANSACTION THROUGH AVAILABLE CASH AND SHORT- AND LONG-TERM BORROWINGS.TRANSACTION IS EXPECTED TO CLOSE IN Q1 OF 2020, SUBJECT TO SATISFACTION OR WAIVER OF ALL CLOSING CONDITIONS.NOVARTIS - EXPECTS DEAL TO BE SIGNIFICANTLY ACCRETIVE TO GROUP CORE OPERATING INCOME AND CORE EPS IN MEDIUM TERM.ASSUMING COMPLETION IN Q1 OF 2020, CO EXPECTS INCLISIRAN TO START TO CONTRIBUTE TO GROUP AND IM DIVISION SALES FROM 2021.

Novartis To Acquire The Medicines Company For $9.7 bln

Sunday, 24 Nov 2019

Nov 24 (Reuters) - Novartis Ag ::REG-NOVARTIS TO ACQUIRE THE MEDICINES COMPANY FOR USD 9.7 BN, ADDING INCLISIRAN, A POTENTIALLY TRANSFORMATIONAL INVESTIGATIONAL CHOLESTEROL-LOWERING THERAPY TO ADDRESS LEADING GLOBAL CAUSE OF DEATH.OFFER PRICE OF USD 85.00 PER SHARE.NOVARTIS - DEAL EXPECTED TO MODESTLY DILUTE CORE EPS VERSUS A NO DEAL SCENARIO DURING NEXT FEW YEARS AS CO INVESTS FOR A SUCCESSFUL LAUNCH OF INCLISIRAN.TRANSACTION HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES.NOVARTIS PLANS TO FINANCE TRANSACTION THROUGH AVAILABLE CASH AND SHORT- AND LONG-TERM BORROWINGS.TRANSACTION IS EXPECTED TO CLOSE IN Q1 OF 2020, SUBJECT TO SATISFACTION OR WAIVER OF ALL CLOSING CONDITIONS.NOVARTIS - EXPECTS DEAL TO BE SIGNIFICANTLY ACCRETIVE TO GROUP CORE OPERATING INCOME AND CORE EPS IN MEDIUM TERM.ASSUMING COMPLETION IN Q1 OF 2020, CO EXPECTS INCLISIRAN TO START TO CONTRIBUTE TO GROUP AND IM DIVISION SALES FROM 2021.

Eli Lilly And Co Says 10% Owner Lilly Endowment Reports Open Market Sale Of 108,264 Shares Of Co's Common Stock

Friday, 22 Nov 2019

Nov 22 (Reuters) - Eli Lilly and Co ::ELI LILLY AND CO SAYS 10% OWNER LILLY ENDOWMENT REPORTS OPEN MARKET SALE OF 108,264 SHARES OF CO'S COMMON STOCK IN MULTIPLE TRANSACTIONS - SEC FILING.ELI LILLY AND CO SAYS LILLY ENDOWMENT REPORTS OPEN MARKET TRANSACTIONS ON NOVEMBER 21, IN PRICE RANGE BETWEEN $115.00 TO $115.51 PER SHARE.

ViiV Healthcare Says To Develop Investigational Antibody N6lS For Treatment Of HIV-1

Thursday, 21 Nov 2019

Nov 21 (Reuters) - ViiV Healthcare: :VIIV HEALTHCARE - TO DEVELOP INVESTIGATIONAL BROADLY NEUTRALISING ANTIBODY N6LS FOR TREATMENT AND PREVENTION OF HIV-1.VIIV HEALTHCARE - DEVELOPMENT OF INVESTIGATIONAL BNAB PART OF LICENSING DEAL BETWEEN GSK, NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES.VIIV HEALTHCARE - TO INITIATE A PHASE IIA STUDY WITH MATERIAL MANUFACTURED BY NIAID VACCINE RESEARCH CENTER.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary